نتائج البحث - Su Pin Choo

تنقيح النتائج
  1. 1
    Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond

    Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond حسب Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

    Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma حسب Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, Su Pin Choo, Masatoshi Kudo

    منشور في 2020
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Comparison of hepatocellular carcinoma in <scp>E</scp>astern versus <scp>W</scp>estern populations

    Comparison of hepatocellular carcinoma in <scp>E</scp>astern versus <scp>W</scp>estern populations حسب Su Pin Choo, Wan Ling Tan, Brian K. P. Goh, Wai Meng David Tai, Andrew X. Zhu

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

    RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma حسب Hung Huynh, Pierce K. H. Chow, Khee Chee Soo, Han Chong Toh, Su Pin Choo, Kian Fong Foo, Donald Poon, Van Chanh Ngo, Evelyn Tran

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90

    A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90 حسب Jin‐Yao Teo, John Carson Allen, David Ng, Su Pin Choo, David Tai, Pik‐Eu Chang, Foong-Khoon Cheah, Pierce K. H. Chow, Brian K. P. Goh

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

    Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma حسب Hung Huynh, Van Chanh Ngo, Heng Nung Koong, Donald Poon, Su Pin Choo, Choon Hua Thng, Pierce K. H. Chow, Hock Soo Ong, Alexander Yaw Fui Chung, Khee Chee Soo

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence

    Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evid... حسب Ye Xin Koh, Hwee Leong Tan, Weng Kit Lye, Juinn Huar Kam, Adrian Kah Heng Chiow, Siong San Tan, Su Pin Choo, Alexander Yaw Fui Chung, Brian K. P. Goh

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

    A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements حسب Masatoshi Kudo, Kwang‐Hyub Han, Sheng-Long Ye, Jian Zhou, Yi‐Hsiang Huang, Shi-Ming Lin, Chung-Kwe Wang, Masafumi Ikeda, Stephen L. Chan, Su Pin Choo, Shiro Miyayama, Ann‐Lii Cheng

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

    Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma حسب Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Andrea Jing Shi Ang, Lawrence Wen Jun Wong, Su Pin Choo, David Tai, Joycelyn Jie Xin Lee

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

    Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis حسب Thomas Yau, Chiun Hsu, Tae‐You Kim, Su Pin Choo, Yoon‐Koo Kang, Ming‐Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda, Ryoko Kuromatsu, Michihisa Moriguchi, Yee Chao, Huanyu Zhao, Jeffrey Anderson, Christine Dela Cruz, Masatoshi Kudo

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma

    Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma حسب Pierce K. H. Chow, Donald Poon, Khin Maung Win, Harjit Singh, Ho‐Seong Han, Anthony Goh, Su Pin Choo, Hee-Kit Lai, Richard Hoau Gong Lo, Kiang‐Hiong Tay, T.W. Lim, Mihir Gandhi, Say‐Beng Tan, Khee‐Chee Soo

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 حسب Anthony B. El-Khoueiry, Jörg Trojan, Tim Meyer, Thomas Yau, Ignacio Melero, Masatoshi Kudo, Chih‐Hung Hsu, T.-Y. Kim, Su Pin Choo, Yubin Kang, Winnie Yeo, Akhil Chopra, Samira Soleymani, J. Yao, Jaclyn Neely, Marina Tschaika, Theodore H. Welling, Bruno Sangro

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

    A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer حسب Allen Lee Cohn, Josep Tabernero, Joan Maurel, Elżbieta Nowara, Javier Sastre, Benjamin Chuah, М. В. Копп, Dina Sakaeva, Edith P. Mitchell, S. Dubey, Samuel Suzuki, Y.J. Hei, Francesco Galimi, Ian McCaffery, Yang Pan, Robert D. Loberg, Susan Cottrell, Su Pin Choo

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

    A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC) حسب Wai Meng David Tai, Wei Peng Yong, Cindy Lim, Lauren Low, Chee Kian Tham, Tong San Koh, Quan Sing Ng, W.W. Wang, L.Z. Wang, Septian Hartano, Choon Hua Thng, Hung Huynh, Kok-Hing Lim, Han Chong Toh, Boon Cher Goh, Su Pin Choo

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma

    Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma حسب Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, Cedric Chuan Young Ng, Jason Yongsheng Chan, Vikneswari Rajasegaran, Tse Hui Lim, Kiat Hon Lim, Su Pin Choo, Simona Dima, Irinel Popescu, Dan G. Duda, Veerapol Kukongviriyapan, Narong Khuntikeo, Chawalit Pairojkul, Steve Rozen, Patrick Tan, Bin Tean Teh

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

    LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular ca... حسب Bruno Sangro, J. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, G. Chen, Jaclyn Neely, Marina Tschaika, Thomas Yau

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

    CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcino... حسب Thomas Yau, J.W. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, G. Chen, Jaclyn Neely, Jeffrey Anderson, Bruno Sangro

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

    A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma حسب Shukui Qin, Stephen L. Chan, Wattana Sukeepaisarnjaroen, Guohong Han, Su Pin Choo, Virote Sriuranpong, Hongming Pan, Thomas Yau, Yabing Guo, Minshan Chen, Zhenggang Ren, Jianming Xu, Chia-Jui Yen, Zhong-Zhe Lin, Luigi Manenti, Yi Gu, Yongjian Sun, Ralph Tiedt, Lu Hao, Wenjie Song, Tawesak Tanwandee

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma

    The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma حسب Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, Ariel Yuhan Ong, Su Pin Choo, Joanne Ngeow, Han Chong Toh, Kiat Hon Lim, Hao Yun Yap, Chee‐Kiat Tan, London Lucien Ooi, Alexander Yaw Fui Chung, Pierce K. H. Chow, Kian Fong Foo, Min‐Han Tan, Peng Chung Cheow

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery

    Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery حسب Sarah B. Ng, Clarinda Chua, Matthew Chau Hsien Ng, Anna Gan, Polly Poon, Melissa Ching Ching Teo, Cherylin Fu, Wei Qiang Leow, Kiat Hon Lim, Alexander Yaw Fui Chung, Si‐Lin Koo, Su Pin Choo, Danliang Ho, Steve Rozen, Patrick Tan, Mark Wong, William F. Burkholder, Iain Beehuat Tan

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: